Lopinavir – Page 11 – Communicable Diseases Research

A complementary critical appraisal on systematic reviews regarding the most efficient therapeutic strategies for the current COVID-19 (SARS-CoV-2) pandemic

현재 COVID-19(SARS-CoV-2) 전염병에 대한 가장 효율적인 치료 전략에 관한 체계적인 검토에 대한 보완적인 비판적 평가

Meta-Analysis

Published on 2021-05-012022-09-11
Journal: Journal of medical virology [Category] SARS, 치료제,

Assessment and management of asymptomatic COVID-19 infection: A systematic review

무증상 COVID-19 감염 평가 및 관리: 체계적인 검토

Article

Published on 2021-05-012022-09-11
Journal: Travel medicine and infectious disease [Category] SARS, 치료제,

[키워드] age assessment Asymptomatic Asymptomatic COVID-19 asymptomatic individual Asymptomatic individuals asymptomatic infection Azithromycin calculate can not case sery Cohort COVID-19 cross-sectional Cross-sectional studies database diagnosis of COVID-19 discharge discharged dissemination FIVE Hospitalization Hydroxychloroquine individual individuals interferon Lopinavir Lopinavir/ritonavir male management Negative PCR nine Patient patients Prevalence proportion random-effects model remained Retrospective study ribavirin Ritonavir SARS-CoV-2 searched shown standard treatment symptomatic systematic review Treatment was used
[DOI] 10.1016/j.tmaid.2021.102058 PMC 바로가기 [Article Type] Article

Peptide-like and small-molecule inhibitors against Covid-19

Covid-19에 대한 펩티드 유사 및 소분자 억제제

Article

Published on 2021-05-012022-09-11
Journal: Journal of biomolecular structure & dynamics [Category] SARS, 신약개발, 치료제,

[키워드] approach approved drugs binding energy binding site carried clinical trials co-crystallized Cobicistat Compound coronavirus disease COVID-19 darunavir database dead disease docked docking docking score docking scores drug Drug repurposing FDA approved drug FDA approved Drugs globe identify in-silico individual inhibitor Interaction interactions Ligand Lopinavir MD simulation MD simulations molecular dynamics Molecular mechanics molecules PDB PDB structure performed positive Potential Protease inhibitor protease inhibitors Protein Protein Data Bank reported Ritonavir SARS-CoV-2 screened Screening selected stability Structure surface area the disease Virtual screening Zinc ZINC database
[DOI] 10.1080/07391102.2020.1757510 PMC 바로가기 [Article Type] Article

Antiretrovirals for Prophylaxis Against COVID-19: A Comprehensive Literature Review

COVID-19 예방을 위한 항레트로바이러스제: 종합 문헌 검토

Review

Published on 2021-05-012022-09-11
Journal: Journal of clinical pharmacology [Category] SARS, 치료제,

[키워드] acute respiratory syndrome Against animal antiretroviral antiretroviral drugs Antiretrovirals article ARV binding affinity clinical evidence cohort study Comorbidity Comprehensive consequence Corona virus Course COVID-19 darunavir database emtricitabine enzyme Evidence expected HIV Human immunodeficiency virus identify immunodeficiency virus in vitro Infection inhibitor literature Lopinavir molecular molecular docking studies nelfinavir nucleoside nucleotide ongoing trial ongoing trials patients Postexposure Prophylaxis Prophylactic Prophylaxis Protease inhibitor protease inhibitors review Ritonavir SARS-CoV-2 SARS-COV-2 infection searched Severe acute respiratory syndrome shown subgroup Support tenofovir the disease virus Virus Disease
[DOI] 10.1002/jcph.1788 PMC 바로가기 [Article Type] Review

Comprehensive evaluation of the efficacy and safety of LPV/r drugs in the treatment of SARS and MERS to provide potential treatment options for COVID-19

COVID-19에 대한 잠재적인 치료 옵션을 제공하기 위해 SARS 및 MERS 치료에서 LPV/r 약물의 효능 및 안전성에 대한 종합 평가

Meta-Analysis

Published on 2021-04-302022-09-10
Journal: Aging (Albany NY) [Category] MERS, 치료제,

[키워드] acute respiratory distress acute respiratory distress syndrome acute respiratory syndrome addition adverse event adverse events age and sex analyzed Antiviral treatment applied ARDS assessment tool benefit bias risk case-control studies CBM Chest CT China CNKI Cochrane Library Cohort studies Combination comprehensive evaluation conducted control group conversion rate coronavirus disease Coronavirus disease 2019 Coronavirus infections COVID-19 COVID-19 treatment database drug effective Effectiveness Efficacy Efficacy and safety eligible evaluate exhibited Factor incidence Infrastructure literature Lopinavir Lopinavir/ritonavir lower mortality LPV/r MERS Meta-analysis Middle East Middle East respiratory syndrome molecular Newcastle-Ottawa Scale NOS nucleic acid outbreak outcome patients patients with COVID-19 patients with SARS performed potential treatment option prognostic Randomized controlled studies RCT reduced Registration respiratory respiratory distress retrieved Risk assessment Ritonavir SARS Severe acute respiratory syndrome significantly similarities similarity statistically significant Structure syndrome systematic review the Newcastle-Ottawa Scale these viruses Treatment treatment of COVID-19 Trial two group two groups virus clearance viruses was used were used
[DOI] 10.18632/aging.202860 PMC 바로가기 [Article Type] Meta-Analysis

Natural tannin extracts supplementation for COVID-19 patients (TanCOVID): a structured summary of a study protocol for a randomized controlled trial

COVID-19 환자를 위한 천연 탄닌 추출물 보충제(TanCOVID): 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2021-04-282022-09-10
Journal: Trials [Category] MERS, SARS, 임상,

[키워드] 1:1 24 hour 24 hours addition Administered administration affected age All trial participants all-cause mortality Alpha alpha error Antibiotic therapy antipyretics assigned assisted ventilation Azithromycin B12 blinded Blinding branch Buenos Aire Buenos Aires can not Chestnut tannins Clinical symptoms clinical trial closure cognitive computer-generated random numbering conditions Consent control group COVID-19 COVID-19 patient criteria cytokine Cytokines Day Decline decrease defined Definition Department described diagnosis of SARS-CoV-2 dietary supplement difference disease dissemination dose double-blind Efficacy element eligibility eligible enrolled Enrollment enrolment epidemiological evaluate excluded fecal Final first dose first visit Gender gut microbiota Hospital de Clínica Hospital de Clínicas Hospital de Clinicas Jose de San Martin hospital discharge Hydroxychloroquine hypersensitivity ICU impaired consciousness increase in indicated Infection Infectious disease Infectious diseases Inflammation inflammatory mediator Inflammatory mediators Informed consent intestinal intestinal permeability invasive ventilation lactating Level Lopinavir mean difference measure mechanical ventilation mediators microbiota modifications molecular natural non-invasive ventilation number objective Older outcome parallel-group parameter participant Participation Patient patients per day Placebo placebo-controlled platform Potential power power of 80% protocol Quebracho tannins randomization Randomized Randomized controlled trial Randomly Real-time PCR receive recruited recruitment Registered Research Ritonavir Sample size SARS-COV-2 infection SARS-CoV2 screened secondary secondary outcome measures severity Standard therapy standard treatment status study participant Study protocol study randomization submitted supplementary material supply tannin tannins therapy time Time frame took place Treatment treatment allocation Trial trial participant Trial registration undergo university Ventilation website
[DOI] 10.1186/s13063-021-05281-x PMC 바로가기 [Article Type] Letter

Epidemiology, clinical characteristics, and treatment outcomes of patients with COVID-19 at Thailand’s university-based referral hospital

태국 대학기반의 위탁병원에서 코로나19 환자의 역학, 임상적 특성 및 치료 결과

Research Article

Published on 2021-04-262022-09-10
Journal: BMC Infectious Diseases [Category] MERS, 치료제,

Current COVID-19 treatments: Rapid review of the literature

현재 COVID-19 치료법: 문헌의 신속한 검토

Review

Published on 2021-04-242022-09-10
Journal: Journal of Global Health [Category] MERS, 임상,

[키워드] acute respiratory syndrome Administered benefit case reports clinical clinical benefit clinical trials clinically Combination convalescent plasma coronavirus coronavirus diseases Corticosteroid Corticosteroids COVID-19 COVID-19 treatments current cytokine Cytokine storm database deaths Effect effective eligible English language faster human coronavirus human coronaviruses Hydroxychloroquine Infection inhibitor interferon Lopinavir lopinavir/ ritonavir MERS Middle East Middle East respiratory syndrome monoclonal antibodies monoclonal antibody Mortality not effective observational studies observational study Outbreaks Rapid Recovery time reduced reducing mortality reflected Remdesivir respiratory Result Ritonavir SARS-CoV-2 searched Severe acute respiratory syndrome severe COVID-19 patients Spread Stage systematic review systematic reviews therapeutic effect therapy Treatment trials WHO
[DOI] 10.7189/jogh.11.10003 PMC 바로가기 [Article Type] Review

Effect of Early Treatment With Hydroxychloroquine or Lopinavir and Ritonavir on Risk of Hospitalization Among Patients With COVID-19 The TOGETHER Randomized Clinical Trial

하이드록시클로로퀸 또는 로피나비르 및 리토나비르를 사용한 조기 치료가 COVID-19 환자의 입원 위험에 미치는 영향 The TOGETHER 무작위 임상 시험

Randomized Controlled Trial

Published on 2021-04-222022-08-13
Journal: JAMA Network Open [Category] MERS, 임상, 진단, 치료제,

[키워드] Administered adverse events age all-cause hospitalization Analysis analyzed assigned benefit Brazil clinical clinical outcomes clinical trial ClinicalTrials.gov Identifier: NCT04403100 conducted country Course COVID-19 COVID-19 pandemic COVID-19 treatment guideline COVID-19 treatment guidelines Cox proportional hazard Cox proportional hazards model data safety monitoring board death determine diagnosed early symptomatic COVID-19 Effect effective Efficacy enrolled Enrollment expedient clinical trial expedient clinical trials fatality finding followed by futility group hazard ratio high-risk patient High-risk patients Hospitalization Hydroxychloroquine hydroxychloroquine group Importance Interim analyses interim analysis Intervention intervention group large-scale outpatient clinical trials Loading dose Lopinavir Lopinavir-ritonavir measure monitoring board no significant difference no significant differences not significantly different objective Odds ratio Outpatient outpatients pandemic participant Participants Patient patients patients hospitalized patients treated Placebo placebo group Point Prevent Primary outcome Primary outcomes proportion proportional hazards model randomization Randomized randomized clinical trial Randomly recorded reduce reducing Registration Relevance Repurposed drug Repurposed drugs respiratory respiratory symptom respiratory symptoms Result Ritonavir Sample size SARS-COV-2 infection secondary outcome self-identified as mixed-race setting statistical analysis symptom resolution symptomatic adult symptomatic adults the median the placebo group Treatment Trial Viral viral clearance was performed with COVID-19 women
[DOI] 10.1001/jamanetworkopen.2021.6468 PMC 바로가기 [Article Type] Randomized Controlled Trial

Efficacy and safety of lopinavir-ritonavir in COVID-19: A systematic review of randomized controlled trials

Article

Published on 2021-04-202023-07-02
Journal: Journal of infection and public health [Category] SARS,

[키워드] COVID-19 Lopinavir Meta-analysis Ritonavir Safety virological cure
[DOI] 10.1016/j.jiph.2021.03.015 PMC 바로가기 [Article Type] Article